Ameriprise Financial Inc Neurocrine Biosciences Inc Transaction History

Ameriprise Financial Inc

$364 Billion
Q2 2024

A detailed history of Ameriprise Financial Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ameriprise Financial Inc holds 413,172 shares of NBIX stock, worth $51.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

413,172

Previous 405,347 1.93%

Holding current value

$51.9 Million

Previous $55.9 Million 1.75%

% of portfolio

0.02%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $1.02 Million - $1.12 Million	7,825 Added 1.93%	413,172 $56.9 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $2.66 Million - $2.93 Million	-20,400 Reduced 4.79%	405,347 $55.9 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $7.73 Million - $9.67 Million	-72,842 Reduced 14.61%	425,747 $56.1 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $153,816 - $191,575	-1,636 Reduced 0.33%	498,589 $56.1 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $4.08 Million - $4.78 Million	-45,599 Reduced 8.35%	500,225 $47.2 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $5.44 Million - $7.11 Million	-57,776 Reduced 9.57%	545,824 $55.2 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $13.4 Million - $15.9 Million	-125,273 Reduced 17.19%	603,600 $72.1 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $4.82 Million - $5.64 Million	52,342 Added 7.74%	728,873 $77.4 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $11.7 Million - $15.5 Million	-154,930 Reduced 18.63%	676,531 $65.9 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $8.98 Million - $11.8 Million	124,005 Added 17.53%	831,461 $77.9 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $40.5 Million - $54.1 Million	508,925 Added 256.35%	707,456 $60.2 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $1.62 Million - $1.86 Million	18,798 Added 10.46%	198,531 $19 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $2.07 Million - $2.37 Million	-23,180 Reduced 11.42%	179,733 $17.5 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $11 Million - $15 Million	125,387 Added 161.74%	202,913 $19.7 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $22.5 Million - $28 Million	-258,713 Reduced 76.94%	77,526 $7.43 Million
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $4.05 Million - $5.69 Million	-42,078 Reduced 11.12%	336,239 $32.3 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $1.12 Million - $1.72 Million	13,178 Added 3.61%	378,317 $47.2 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $1.94 Million - $2.95 Million	25,895 Added 7.63%	365,139 $31.5 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $28.2 Million - $38.5 Million	325,055 Added 2290.89%	339,244 $36.6 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $1.05 Million - $1.27 Million	-12,475 Reduced 46.79%	14,189 $1.28 Million
Q2 2019 Aug 14, 2019	SELL	$72.24 - $91.27 $29,979 - $37,877	-415 Reduced 1.53%	26,664 $2.25 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $1.6 Million - $2.11 Million	23,064 Added 574.45%	27,079 $2.39 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $15,167 - $27,607	-222 Reduced 5.24%	4,015 $287,000
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $23,039 - $29,323	233 Added 5.82%	4,237 $521,000
Q2 2018 Aug 14, 2018	SELL	$75.3 - $105.99 $1.34 Million - $1.89 Million	-17,802 Reduced 81.64%	4,004 $393,000
Q1 2018 May 15, 2018	SELL	$75.88 - $92.43 $6.38 Million - $7.77 Million	-84,079 Reduced 79.41%	21,806 $1.81 Million
Q4 2017 Feb 12, 2018	BUY	$58.53 - $77.59 $4.64 Million - $6.15 Million	79,244 Added 297.45%	105,885 $8.22 Million
Q3 2017 Nov 07, 2017	BUY	$47.97 - $61.28 $1.28 Million - $1.63 Million	26,641	26,641 $1.63 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account

Ameriprise Financial Inc Neurocrine Biosciences Inc Transaction History